Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Endometrial Cancer
When do you consider adjuvant chemotherapy and/or RT for stage I-III high-grade uterine sarcomas s/p resection?
Related Questions
For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?
What is your preferred adjuvant therapy for IIIC high-grade endometrioid endometrial adenocarcinoma with positive microscopic paracervical margins?
Do you offer resection of oligometastatic disease for patients with recurrent uterine serous carcinoma within the pelvis following initial treatment with adjuvant chemotherapy and vaginal cuff brachytherapy?
What adjuvant therapy would you recommend for IA G3 endometrioid endometrial adenocarcinoma with no LVSI, MMR intact, p53wt and POLEmut?
How would you manage a patient with FIGO 2018 IA G3 endometrioid adenocarcinoma with substantial LVSI, and was N- with adequate nodal staging?
What are your image guidance instructions for post-op endometrial cancer EBRT?
Do you recommend a completion hysterectomy to patients who undergo primary radiation for endometrial cancer (presuming they are now a surgical candidate)?
Would you consider offering immunotherapy +/- olaparib to a patient with early-stage endometrial carcinoma for whom you are recommending adjuvant chemotherapy based on improved outcomes seen in RUBY/DUO-E/NRG-GY018?
For a patient with IIIC endometrial adenocarcinoma diagnosed and treated with 6 cycles of Carboplatin/Paclitaxel two years prior, would you consider maintenance therapy with PD-L1 inhibition, given results of GY018 and RUBY?
Would you offer pelvic radiation in a patient with Stage IIIC endometrial cancer who has Crohn's disease and a permanent ileostomy?
